The present disclosure provides compositions and methods of restoring or enhancing visual function in an individual by administering to the individual a pharmaceutical composition comprising a recombinant adeno-associated viral (rAAV) vector having a polynucleotide sequence that encodes a medium wavelength cone opsin (MW-opsin). The MW-opsin is expressed in a retinal cell in the individual, thereby restoring or enhancing visual function.

Alpha-sheet polypeptide multimers, and polypeptides for making multimers, compositions and medical devices including them, and their use for treating and diagnosing amyloid diseases or amyloid-associated diseases are disclosed.

Provided herein are methods and compositions for treating solid tumor cancers.

Provided herein are methods and compositions for treating solid tumor cancers.

Food composition supplemented with one or more honey proteins provide additional protein without detracting from flavor or mouthfeel and may also possess cytostimulatory properties. The honey proteins may be royal jelly major proteins (RJMP) such as those from the western honeybee Apis mellifera. The honey proteins can be created by expression of recombinant DNA in a yeast or bacterium. The honey protein is selected based on physical properties of the protein and of the food composition to reduce negative mouthfeel and flavor characteristics that may be caused by added protein. Multiple different proteins may be added in a specified ratio to create a desired texture or cytostimulatory property.

Disclosed are an amphiphysin-I mutant having anti-senescence activity and the use thereof. More particularly, disclosed are an amphiphysin-I mutant (AMPH-I) wherein valine (V), which is the 392nd amino acid in the amino acid sequence of amphiphysin-I (AMPH-I) represented by SEQ ID NO: 1, is substituted with glycine (G), a composition for suppressing aging and cellular senescence containing the amphiphysin-I mutant as an active ingredient, a pharmaceutical composition for preventing or treating senescence or a senescence-associated disease, a method for suppressing aging and cellular senescence, and a method for screening an inhibitor for aging and cellular senescence. The amphiphysin-I mutant is capable of suppressing both promotion of aging and cellular senescence and reduction of endocytosis caused by suppression of expression of βPIX (PAK1-interacting exchange factor beta), of preventing cleavage of the amphiphysin-I protein caused by calpain, a protease involved in aging and cellular senescence caused by suppressed βPIX expression, and of suppressing the expression of aging and cellular senescence indicators. Thus, the amphiphysin-I mutant is effectively used as a novel therapeutic agent for senescence or senescence-associated diseases.

Compositions and methods for treating a VEGF-related ophthalmic disorder in a subject in need comprising, administering intravitreally to the subject a therapeutically effective amount of an anti-VEGF agent, comprising a VEGF binding portion operatively linked to a Fc-IgG, wherein the VEGF binding portion comprises at least one VEGF binding domain that is an IgG-like domain 2 of VEGFR-1.

The present invention relates to oral composition and the method of preparation and use of such composition for inhibiting, reducing, and/or disrupting oral biofilm. The composition comprises a stabilizing matrix, a cationic biocide, and a peroxide source.

In some aspects, fusosome compositions and methods are described herein that comprise membrane enclosed preparations, comprising a fusogen. In some embodiments, the fusosome can the target cell, thereby delivering complex biologic agents to the target cell cytoplasm.

With years of disease progression, a small amount of albumin in the blood of nephropathy patients started to leak into the urine, however very likely to be ignored due to mild clinical symptoms or confused with proteinuria caused by hypertension and/or hyperlipidemia with progress. But when other biomarkers of renal function are also found significantly increased in urine, such as β2 microglobulin α1 microglobulin, transferrin and immunoglobulin, the renal function has been impacted by pathological changes. At present, there is no effective method except hormone for nephropathy proteinuria treatment, and long-term hormone treatment will bring many side effects to patients. If the course of disease progresses freely, more protein will leak into the urine, and the renal damage will be getting worse. Cobrotoxin polypeptide molecule can effectively reduce the leakage/proteinuria, control and delay the renal pathological progression and improve renal function by inhibiting the autoimmune inflammatory response of kidney, thus contribute significantly to the treatment of nephropathy.